- Last sale
- Nov 12, 2026 · -3.44%
- Market cap
- $5.45B
- 44.96M shares
- Filings
- 269
Q3 2026+17.2% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+16.6% FY25 yoy
- $5.45B
- —
- 32.7×
- 2.2×
- -5.72%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $147,172,000 | reported | |
| FY 2024 | 2024-12-31 | $125,595,000 | reported | |
| FY 2023 | 2023-12-31 | $93,105,000 | reported | |
| FY 2022 | 2023-01-01 | $55,550,000 | reported |
Segments
Products
LineFY2025ShareChange
Screening revenue$138.60M94%+27.6%
Development Services$8.57M5.8%−49.5%
Total$147.17M
Medical laboratories
Grail, Inc. is the 13th largest of the 29 covered companies the SEC files under this code, by revenue. SIC 8071
CompanyRevenueGrowthNet marginMarket cap
CSTLCastle Biosciences Inc$344.2M3.7%7.0%$1.1BFLGTFulgent Genetics, Inc.$322.7M13.8%18.8%$693.9MBLLNBillionToOne, Inc.$305.1M100.0%2.4%$5.3B
GRALGrail, Inc. (this company)$147.2M17.2%277.5%$5.5B
MDXHMDxHealth SA$107.9M19.8%31.1%$7.2MBDSXBiodesix Inc$88.5M24.1%39.8%$108.8MBNRBurning Rock Biotech Ltd$77.2M9.2%10.3%$151.0MPSNLPersonalis, Inc.$69.6M17.7%116.7%$1.7BXGNExagen Inc.$66.6M19.7%30.0%$194.0MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Grail, Inc. · CIK 1699031 · Engraved from SEC EDGAR